Cell Grand Clinic: Your Own Cells, Never a Donor’s, Under Japan’s National Safety Law for Regenerative Medicine
Your own stem cells — never a donor’s, never pooled. Fourteen government-approved treatment plans. One physician, first email to final follow-up. Osaka, Japan.
Whose cells go into your body — your own, or a stranger’s? And once you have flown home, who is still accountable? Cell Grand Clinic (CGC), a boutique regenerative-medicine practice on Osaka’s central Midosuji avenue, answers with claims a patient can check: the cells are your own, cultured individually and never pooled, and each therapy holds a formal provision plan approved under Japan’s national regenerative-medicine safety law. Medical Tourism Magazine spoke with the clinic about how it works, whom it treats, and what a patient’s stay looks like. Patients can view treatments and submit an inquiry through the clinic’s Better by MTA profile.
Click here to submit an inquiry.
Who is Cell Grand Clinic, and where are you based?
We are a private regenerative-medicine clinic, founded in 2025, on Osaka’s central Midosuji avenue in Shinsaibashi. By design we are a boutique practice led by a single physician, Dr. Yuichi Wakabayashi, and our core treatment is autologous adipose-derived stem cell therapy — cells taken from the patient’s own body — supported where appropriate by exosome therapy and NMN. We chose the physician-led model deliberately. Regenerative medicine, done responsibly, is a continuity business, not a volume one. Scale into many doctors across many sites, and the thing an international patient most needs — one person who knows their case from first email to last follow-up — is the first to break.
Whom do you treat from abroad, and where do they come from?
Patients have come to us from roughly twenty countries, and Dr. Wakabayashi has performed more than three thousand adipose-derived stem cell procedures over his career. We keep annual volume modest on purpose: it is what lets one physician stay personally responsible for each case, so the person who evaluates you is the same one who treats you and follows up months later. Dr. Wakabayashi counsels international patients directly in English, with no interpreter between the doctor and the person deciding whether to travel. The facility also has Chinese-speaking staff on site and a halal-friendly area, in a neighborhood patients and their families find easy to stay in.
What is the one thing that sets your treatment apart?
We use the patient’s own cells, and we never pool them. That single line separates us from much of the field. A great deal of the stem cell therapy marketed to international patients uses donor cells — sourced from someone else, often combined across multiple donors into shared batches. We do neither. Ask any clinic abroad two plain questions — are these my own cells, and were they ever mixed with anyone else’s? — and you deserve a plain answer. Ours is: your own, and never mixed.
The quality standard behind that principle:
- • Autologous only — your own adipose-derived cells, never a donor’s
- • Never pooled — each patient’s cells cultured individually, in their own dedicated line
- • Stopped at Passage 3 — to preserve the cells’ natural character, not over-expand them to stretch a batch
- • ISCT-standard identity check — the markers CD73, CD90 and CD105 confirmed at near-total levels
- • Released only above 95% viability — with the result documented
A patient never has to memorize the immunology. Each check exists, is documented, and confirms the cells were never anyone else’s.
How is your treatment regulated — and how is that different from a clinic simply being licensed?
In many countries, a clinic’s reassurance is an operating permit — proof the facility is allowed to open. Japan asks for more. Under the Act on the Safety of Regenerative Medicine, each treatment itself must be reviewed by a certified committee and approved before any patient can receive it. Cell Grand Clinic holds fourteen such approved plans — eleven of them in the higher-risk Type-2 category, which requires the more rigorous review, plus three in the lower-risk Type-3, with Alzheimer’s disease among them — one of the largest counts of any clinic in Osaka. In other words, it is not the building that is approved here, but each specific therapy, for each specific condition — the distinction international patients most often miss.
Who actually treats the patient?
One physician, from beginning to end. Dr. Wakabayashi personally handles every stage — the initial inquiry, the evaluation, the adipose harvest, oversight of the cell culture, the administration of the therapy, and follow-up at one, three and six months. There is no handoff between a consulting and a treating doctor, and no rotation of staff between visits.
His background is why we can make that promise credibly. He holds an MD and a PhD and trained as a research fellow at the U.S. National Institutes of Health. He is board-certified by the American Board of Regenerative Medicine — a specialty board in this exact field, not a general or honorary title — and has performed more than three thousand adipose-derived stem cell procedures for patients from some twenty countries. He has published six peer-reviewed English-language papers, including work on Alzheimer’s disease and PDE4 research carried out with Pfizer, and counsels patients directly in English. He has also undergone both stem cell and exosome therapy himself — which we mention deliberately: a physician who has been his own patient counsels more honestly about what these therapies can and cannot do, including telling a patient before treatment, not after, when a good result is unlikely.
What does a patient’s journey look like?
The journey is built around two visits to Osaka, in four stages:
- 1. Before you fly — an online consultation in English with Dr. Wakabayashi, so suitability and price are settled before anyone books a flight. No one should cross an ocean only to be told at the door they are not a candidate.
- 2. First visit — the adipose harvest, performed the same day, with exosome or PRP treatment for some symptomatic relief while the cell line is prepared.
- 3. The culture window — roughly seven weeks, during which the patient’s cells are grown individually in their own dedicated line.
- 4. Second visit and follow-up — administration of the cultured cells, then structured follow-up at one, three and six months with the same physician, whether the patient is back in Osaka or checking in from home.
The facility is built for this: a fully private clinic in a prime Shinsaibashi location, with up to four IV suites running at once, Chinese-speaking staff on site, a halal-friendly area, and a central neighborhood patients and their families find comfortable.
What treatments and procedures do you offer?
Our care centers on three areas — knee osteoarthritis, diabetes (Type 1 and Type 2), and anti-aging and preventive medicine — with a wider set of therapies around them. Across our approved provision plans, we currently treat:
- • Orthopedic and pain: — knee osteoarthritis and chronic pain
- • Metabolic: — diabetes, Type 1 and Type 2
- • Anti-aging and preventive: — a flagship whole-body protocol combining two hundred million of the patient’s own adipose-derived stem cells with exosomes
- • Neurological: — Alzheimer’s disease, among our approved plans
- • Men’s health, hair and skin: — erectile dysfunction, hair loss (AGA and FAGA), and skin conditions
Several further therapies — for stroke, arteriosclerosis, atopic conditions, kidney disease and autoimmune disease — we expect to add as each provision plan is formally approved. Our menu expands only as new plans clear national review; we would rather grow one approved treatment at a time than advertise conditions we are not yet cleared to treat. For the same reason, we publish no paid testimonials and present no single success story as the rule. A focused, honest menu is worth more to a patient making a serious decision than a comprehensive-sounding one.
How do you see the future of medical travel?
Regenerative medicine is becoming a genuine third option for patients whom drugs and surgery have left behind — those for whom medication only manages symptoms, and those for whom an operation is premature or unwanted. But the field will only earn lasting trust if it stops selling on luxury and longevity slogans and starts proving on specifics: which cells, whose cells, which approval, which named physician, and what accountability there is after the patient goes home. Those are exactly what a careful patient is advised to look for — transparency in communication and pricing, care that is properly reviewed and licensed, real diagnostics and honest eligibility screening, no exaggerated claims, and genuine long-term follow-up. We have tried to build a clinic that satisfies every one of those on the record rather than in a promise.
That approach has drawn recognition: CGC was named a Top Regenerative Medicine Solution in APAC 2026 by Healthcare Business Review APAC, is a member of Medical Excellence JAPAN, and has been featured in The Wall Street Journal. But the recognition we care about most is the kind a patient can verify — which cells, which approval, which physician — long after any award.
Cell Grand Clinic offers autologous stem cell therapy from USD 19,800 per session. Patients can view treatments and submit an inquiry through the clinic’s Better by MTA profile.
